Lenacapavir HIV Prevention Injection to Reach Too Few

Original Article by Chris Bateman | Financial Mail | 5 February 2026

South Africa’s first consignment of lenacapavir, a six-monthly HIV prevention injection for high-risk HIV-negative people, will cover fewer than a quarter of the target population. Deliveries are underway and will continue through April. Rollout will begin immediately after delivery, with an initial two-year implementation plan. Lenacapavir has been described as an HIV game-changer because trial […]

South Africa’s first consignment of lenacapavir, a six-monthly HIV prevention injection for high-risk HIV-negative people, will cover fewer than a quarter of the target population. Deliveries are underway and will continue through April. Rollout will begin immediately after delivery, with an initial two-year implementation plan. Lenacapavir has been described as an HIV game-changer because trial…

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

Older Adults With HIV Set To Double By 2040

Older adults with HIV will nearly double by 2040. South Africa faces one of the sharpest rises, straining health systems.

Read more...

Rosebank Health Village Expands Growthpoint Portfolio

Rosebank Health Village, a R100 million Growthpoint and Epione development, brings specialists, diagnostics and day surgery together.

Read more...

Global HIV Funding Cuts Put AIDS Progress At Risk

Global HIV funding cuts pushed financing to a 20-year low in 2025, threatening prevention, research and the goal of ending AIDS by 2030.

Read more...